Dear Secretary Kennedy:
On behalf of the Endocrine Society, I am writing regarding the interim policy to allow the compounding of six unapproved injectable peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Founded in 1916, the Endocrine Society represents approximately 18,000 physicians and scientists engaged in the management and research of endocrine disorders, including obesity. The Society is at the forefront of research and clinical practice using new hormone-based therapies to treat obesity and related medical problems. Many of our members have specific expertise in understanding injectable peptides and in obesity research, prevention, and treatment.
I would like to express the Endocrine Society’s opposition to this proposal and urge you not to move forward with this interim policy. There is a lack of clinical evidence and research on all six of these injectable peptides.